GlassScriptPhysician profile
Rita Kapoor
NPI 1699199281
$3,074.99
in general payments reported to CMS, 2019-2025
27 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.45 · 2021: $153 · 2022: $314 · 2023: $516 · 2024: $970 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $541.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $429.11 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $286.64 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $283.40 | 2022-2024 | Xarelto |
| Astellas Pharma US INC | $196.19 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $183.38 | 2022-2025 | |
| Daiichi Sankyo INC. | $158.60 | 2024 | Injectafer |
| Amgen INC. | $144.06 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $127.38 | 2024-2025 | |
| Abbott Laboratories | $98.48 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $85.69 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.79 | 2021-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $66.48 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $57.08 | 2024-2025 | Zepbound, Mounjaro |
| Inspire Medical Systems, INC. | $55.70 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $44.84 | 2021-2023 | |
| Amarin Pharma, INC. | $41.88 | 2021-2022 | |
| Nevro Corp. | $30.62 | 2024 | Senza |
| Ani Pharmaceuticals, INC. | $23.59 | 2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $21.08 | 2022 | |
| Almatica Pharma LLC | $20.36 | 2024 | Loreev Xr |
| Esperion Therapeutics, INC. | $20.27 | 2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $19.90 | 2022 | |
| Medtronic, INC. | $18.74 | 2024 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.10 | 2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2025 | Eliquis |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.